Floatz logo

ibi354

Fallopian Tube Cancer

Innovent Biologics (Suzhou) Co. Ltd.Phase 3Active
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
65/ 100

Competitive context

124 Active assets in the Fallopian Tube Cancer cohort.

Asset / SponsorPhaseRating
Mirvetuximab Soravtansine
AbbVie
Phase 3BB
Inno-206
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3BB
Irinotecan
Tianjin Medical University Cancer Institute and Hospital
Phase 3BB
Carboplatin
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
GOG Foundation
Phase 3BB

View all 50 →

Same molecule, other indications

ibi354 is also rated in:

primary peritoneal carcinomaDormant
B
Indicative ·
60 / 100
View asset →
ovarian disorderDormant
B
Indicative ·
60 / 100
View asset →
HER2 positive breast carcinomaDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →